XERS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XERS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Xeris Biopharma Holdings has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Xeris Biopharma Holdings Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Xeris Biopharma Holdings did not have earnings to cover the interest expense. Xeris Biopharma Holdings's debt to revenue ratio for the quarter that ended in Dec. 2023 was 1.29. As of today, Xeris Biopharma Holdings's Altman Z-Score is -1.84.
For the Biotechnology subindustry, Xeris Biopharma Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Xeris Biopharma Holdings's Interest Expense for the months ended in Dec. 2023 was $-7.0 Mil. Its Operating Income for the months ended in Dec. 2023 was $-9.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $225.7 Mil.
Xeris Biopharma Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is
Xeris Biopharma Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Xeris Biopharma Holdings's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (3.495 | + | 225.696) | / | 177.56 | |
= | 1.29 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Xeris Biopharma Holdings has a Z-score of -1.84, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -1.84 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (NAS:XERS) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Xeris Biopharma Holdings has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey W Sherman | director | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Steven Pieper | officer: Chief Financial Officer | XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601 |
Dawn Halkuff | director | C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601 |
Shannon John Patrick Jr | officer: See Remarks | DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960 |
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Paul R Edick | director, officer: See Remarks | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Ricki Louise Fairley | director | XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601 |
Steven Prestrelski | officer: Chief Scientific Officer | C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601 |
Beth Hecht | officer: See Remarks | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
Kenneth Erland Johnson | officer: See Remarks | C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601 |
Barbara-jean Anne Bormann-kennedy | director | 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144 |
Marla Persky | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Garheng Kong | director | 712 COLLEGE AVENUE, MENLO PARK CA 94025 |
Barry M. Deutsch | officer: See Remarks | OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015 |
From GuruFocus
By Business Wire Business Wire • 01-30-2023
By Business Wire Business Wire • 02-23-2023
By Business Wire • 01-05-2024
By Business Wire • 07-31-2023
By Business Wire • 01-10-2024
By Business Wire Business Wire • 05-02-2023
By Business Wire Business Wire • 11-02-2022
By Business Wire Business Wire • 01-05-2023
By Business Wire Business Wire • 02-02-2023
By Business Wire Business Wire • 11-23-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.